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Sarah Falk ,   Tamara Al-Dihaissy , Laura Mezzanotte , Anne-Marie Heegaard1
Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, 2100, Denmark
Department of Radiology, Leiden University Medical Center, Leiden, 2333 ZA, Netherlands
Abstract
An overwhelming amount of evidence demonstrates sex-induced variation in
pain processing, and has thus increased the focus on sex as an essential
parameter for optimization of in vivo models in pain research. Mammary cancer
cells are often used to model metastatic bone pain in vivo, and are commonly
used in both males and females. Here we demonstrate that compared to male
rats, female rats have an increased capacity for recovery following inoculation
of MRMT-1 mammary cells, thus potentially causing a sex-dependent bias in
interpretation of the data.
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            Amendments from Version 2
Further elaboration on the main results was added to the 
discussion. In addition, a section on estrogen-receptor status was 
added.
See referee reports
REVISED
Introduction
A crucial step in translational research is development of animal 
models that can accurately mimic the human condition in relation 
to both symptoms and underlying mechanisms1,2. To understand the 
molecular mechanism of complex human disease, and thereby cre-
ate disease-specific treatment, the models need to be reproducible 
and with a high predictive value, requiring a detailed knowledge 
of the expected variation in the models used. Cancer-induced bone 
pain is a highly complex pain state involving cancer cells, bone cells, 
immune cells as well as neuronal and non-neuronal processing in 
the periphery and at spinal and supraspinal levels3. Numerous stud-
ies have reported on variation in the more than 45 animal models 
that have been used to model the pain state4. The most common vari-
ations are related to cell lines, species or injection site used4, and in 
addition we have previously demonstrated that sex does also affect 
the model5, thereby emphasizing the need to consider sex bias.
The majority of preclinical pain research is still performed using 
male animals, despite an overwhelming amount of both human and 
animal data demonstrating significant sex variations6–8. Conversely, 
within the field of bone cancer pain, preclinical researchers have had 
more focus on the issue, likely due to a more intuitive choice of sex, 
based on the origin of the cancer cells used. A meta-analysis of stud-
ies on cancer-induced bone pain demonstrated that 49% of the stud-
ies used males, 22% used females and 29% did not report the sex of 
the animals used4. These numbers are indeed more balanced than the 
numbers previously reported, revealing that 79% of all animal stud-
ies published in PAIN from 1996 to 2005 were using male animals, 
whereas only 8% used females8. However, in this study we demon-
strate that not only is sex an integral factor to be considered when 
choosing an animal model, intrinsic sex-dependent variation has to 
be carefully analyzed in order to avoid bias. The data presented in 
this study suggest, that in the MRMT-1-Luc2 carcinoma cell model 
of metastatic bone cancer pain, a sex-dependent bias related to 
recovery is skewing the behavioral responses observed in females 
to a greater extent compared to males, potentially masking effects in 
studies where female animals are used to model the pain state.
Methods
Experiments were performed on 10 male and 10 female Sprague-
Dawley rats (Taconic M&B, Denmark) group-housed in cages 
under a 12-h alternating light/dark cycle with ad libitum access to 
food and water. In addition, unpublished data from four previous 
independent in-house experiments were analyzed; these included a 
total of 16 females and 42 males, and were performed as described 
in this method section (see Figure 4C). The only difference with 
respect to methods is that three experiments were performed prior to 
transfection of the MRMT-1 cells line, and this study and one of the 
prior experiments were conducted after transfection of the MRMT-1 
cells line. For all animals bodyweight and general health was 
monitored throughout the studies. All experiments were approved 
by the Danish Animal Experiments Inspectorate under the Danish 
Ministry of Food, Agriculture and Fisheries (2014-15-0201-00031), 
and were carried out in accordance to the guidelines of the Commit-
tee for Research and Ethical Issues of the International Association 
for the Study of Pain9.
Generation of MRMT1-Luc2
Generation of MRMT1 cells expressing reporter proteins was 
achieved by genomic integration of the Luc2-copGFP reporter 
gene construct using lentiviral transduction. The lentiviral vec-
tor contains the EF1α promoter sequence driving the equimolar 
expression of a codon-optimized firefly luciferase (Luc2) gene 
and a copepod green fluorescent protein (copGFP) thanks to the 
presence of a T2A sequence. Vector production and cell transduc-
tion were performed under appropriate biosafety level conditions 
(ML-II) in accordance with the National Biosafety Guidelines and 
Regulations for Research on Genetically Modified Organisms. Pro-
cedures and protocols were reviewed and approved by the LUMC 
Biosafety Committee (GMO permit 08-129). Vector production and 
transduction procedures have been described in detail elsewhere10. 
In brief, cells were seeded in 24-well plate at a cell density of 
7.5×104 cells/well and maintained in a humidified incubator at 
37°C and 5% CO2. After attachment was accomplished, the cells 
were transduced using a MOI (multiplicity of infection) of 1. Sub-
sequently cells were FACS sorted for high expression of copGFP 
and cell culture was expanded for experiments.
Cell culture
Syngeneic MRMT1-Luc2 rat mammary gland carcinoma cells 
(Leiden University medical Center, The Nederlands) were cultured 
in RPMI 1640 medium without phenol red (Invitrogen, Paisley, 
UK/Nærum, Denmark) supplemented with 10% heat-inactivated 
foetal bovine serum, 1% L-glutamine and 2% penicillin/streptomycin 
(Invitrogen, Paisley, UK/Nærum, Denmark). On the day of surgery, 
MRMT1-Luc2 carcinoma cells were released by brief exposure to 
0.1% w/v trypsin-EDTA and centrifuged in medium for 3 min at 
1200rpm. The pellet was washed twice with Hanks’ balanced salt solu-
tion (HBSS) without calcium, magnesium or phenol red (Invitrogen, 
Paisley, UK/Nærum, Denmark) and centrifuged for 3 min at 1200rpm. 
Cells were re-suspended in HBSS and kept on ice until use.
Surgery
The inoculation of carcinoma cells was performed modified from 11 
as previously described12. Hence, following induction of isoflurane 
anaesthesia (induction 4%, maintenance 1.5–2%) the animal was 
placed with the abdominal side up. A small incision was made in 
a shaved and disinfected area on the anterior-medial surface of 
the tibia and the tibia carefully exposed. A hole was made in the 
tibia with a 0,7mm dental drill through which a thin polyethylene 
tube was fed 1cm into the proximal intramedullary cavity. Animals 
were injected with 5×103 MRMT1-Luc2 carcinoma cells in 10µl 
HBSS. Following removal of the tube, the hole was plugged with 
bone restorative material (IRM, Dentsply, Surrey, UK/Vallensbæk, 
Denmark). The wound was irrigated with saline and closed with 
two metal clips. The animals were placed under a heat source until 
fully awake. Postoperative analgesia was administrated by injection 
of Rimadyl (s.c. 5mg/kg, Pfizer, Denmark) and application of 2% 
Lidocaine gel (AstraZeneca, Denmark) to the wound.
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Behavioral tests
Behavioral responses were assessed prior to surgery and on day 7, 
10, 14, 17, 21 and 23. All animals were introduced to all behavioral 
tests 2–3 times prior to the start of the experiment. Animals reach-
ing humane endpoint before day 23 (n=7) (predefined as limb use 
score 0) were euthanized by decapitation following brief exposure 
to isoflurane, and the behavioral scores from the last day carried 
forward for data analysis.
Von Frey test. Mechanical hypersensitivity, detected by von Frey 
filaments (North Coast Medicinal, Inc., Camino Arroyo, Gilroy, 
CA, USA), was used as an indicator of early pain behavior. The 
threshold was determined by the up and down method, as described 
previously13. Briefly, rats were placed in acrylic enclosures on a 
wire mesh floor and allowed to acclimatize for minimum 30 min. 
Starting at 6 g, filaments ranging from 0.4–26 g were applied to the 
plantar surface of the hind paw with a minimum of 3 min intervals 
between two stimulations. A stimulus was recorded as positive if 
paw withdrawal was observed within 3 s of stimulation with a given 
filament; if no response was observed it was recorded as negative. 
Following a positive response, the next stimulation was performed 
with a filament with a decreased bending strength, whereas a nega-
tive response was followed with stimulation with a filament with 
increased bending strength. According to the original protocol, opti-
mal threshold calculation by this method requires 6 responses in 
the immediate vicinity of the 50% threshold, therefore recording of 
the 6 data points did not begin until the response threshold was first 
crossed (positive response changes to negative response or inverse). 
The 2 responses detecting the threshold were designated as the first 
2 responses of the series of 6. In cases where continuous negative 
responses were observed to the maximum of the stimulus set, a value 
of 26 g was set as the cut-off and used as withdrawal threshold for 
data analysis. In all other cases the resulting pattern of positive and 
negative responses was calculated into a 50% response withdrawal 
threshold using the formula: 50% g threshold = (10Xf+kδ)/(10,000), 
where Xf = value (log unit) of the final von Frey hair used; 
k = tabular value for the pattern of positive/negative responses; and 
δ = mean difference (in log units) between filaments.
Weight-bearing test. Rats were placed in the incapacitance tester 
(MJS Technology Ltd., Buntingford, Herfordshire, UK) and 
allowed to acclimatize until calm. Measurements were performed 
over a period of 4 s and in triplicates. An average weight-bearing 
ratio was subsequently calculated as the amount of weight placed 
on the cancer-bearing leg divided by the total amount of weight 
placed on both legs and used for data analysis.
Limb use test. Rats were allowed to move freely in a transparent 
plastic cage without bedding (500 mm × 300 mm × 500 mm). Fol-
lowing 10 min of acclimation, each animal was observed for 3 min 
and assigned a limb use score from 3 to 0 as follows: 3: Normal 
use of leg, 2: mild or insignificant limping, 1: significant limping, 
0: significant limping and part lack of use.
Bioluminescence imaging
Animals were anesthetized in an induction chamber with 2.5% iso-
flurane (Isobar Vet; 100%, Nomeco, Copenhagen, DK). D-Luciferin 
(PerkinElmer, Skovlunde, Denmark) dissolved in PBS was 
administered by intraperitoneal injection (40mg/kg). 10 min after 
injection, animals were placed on their back in a nose cone in a 
Lumina XR instrument (Caliper Life Sciences, Teralfene, Belgium) 
and anesthesia was maintained with a 2.5% isoflurane/oxygen mix. 
Image capture was performed with binning: M(4), F/stop: 1 and 
exposure time from 1 s to 60 s according to the power signal. The 
signal was adjusted according to the exposure time prior to data 
analysis. For each animal, an average of three images was used 
for analysis. Between each capture, the animal was repositioned to 
minimize bias caused by placement of the animals in the machine. 
Bioluminescence images were analyzed using IVIS Imaging 
Software (Living Image©, version 4.0.0.9801; Caliper Life Sciences, 
Teralfene, Belgium). For each image, the threshold was adjusted 
to 35% of the signal, and the readout was measured in total flux, 
photos/s.
X-ray analysis
X-Ray images were captured subsequent to the bioluminescence 
images. The severity of bone degradation was analyzed using 
ImageJ (ImageJ 1.47v). Each X-Ray image was calibrated to a 
standard aluminum wedge. The mean grayscale value of a standard 
region of interest within the trabecular bone of the proximal tibia 
was measured and the average of two corresponding background 
regions in the soft tissue proximate to tibia was subtracted. The 
grayscale value was translated into millimeter aluminum equiva-
lents (mmAl) according to the standard wedge and used as estimate 
of the relative bone density of the distal femur. Data analysis was 
blinded for sex of the animals.
Determination of active state
Animals with no bioluminescence signal or lack of osteolysis, 
hence no active cancer growth, were excluded from the active state 
group. All animals included in this study were assigned to an active 
or restored state based on presence of bioluminescence signal and 
osteolysis (active) or lack of bioluminescence signal and osteoly-
sis (restored). Four previous in-house experiments were reanalyzed 
with regard to active and restored state based on presence biolumi-
nescence signal and osteolysis or lack of bioluminescence signal 
and osteolysis, or based on osteolysis or lack of osteolysis alone. 
One study was similarly using bioluminescence as exclusion crite-
ria, whereas the data from the three previous studies was analyzed 
with respect to lack of osteolysis. Lack of osteolysis was based on 
the last measure day, usually day 21–23, whereas one experiment 
was terminated at day 14, however on this day 10 out of 11 animals 
showed clear osteolysis.
Adverse events
No adverse events were observed during the experiment.
Statistical analysis
All analyses were blinded for the researchers. Analyses were per-
formed using GraphPad Prism 6, (GraphPad Software, CA, USA), 
and for all data a 95% confidence interval was used as a measure of 
statistical significance. All data are expressed as mean ± standard 
error of mean (S.E.M.). In vitro analysis of bioluminescence signal 
was analyzed with linear regression. Behavioral, bone degradation 
and tumor progression data were analyzed using two-way repeated 
measure ANOVA followed by Bonferroni post-hoc test to compare 
baseline values to each additional time point, and in addition to com-
pare females to males. Analysis of odds ratio of cancer clearance was 
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tested using Chi-square test. Level of significance for all tests was set 
at */#p < 0.05, **/##p < 0.01, ***/###p < 0.001, ****/####p < 0.0001.
Results
Validation of bioluminescence emission in cancer cells
The bioluminescence signal was evaluated to validate successful 
transfection of Luc2 into the MRMT-1 carcinoma cells. In vitro, 
the signal increased linearly with the number of cells, p <0.0001 
(Figure 1A). In vivo, i.p. administration of D-Luciferin induced a 
robust plateau of the bioluminescence signal 5 min after injection 
and lasting approximately 20min (Figure 1B). Luc2 was hence suc-
cessfully transfected into the carcinoma cells, linearly reflecting the 
number of living cells in vitro, and produced a robust signal in vivo.
Sex-dependent variation in disease progression
Pain behavior was quantified by detection of mechanical hypersen-
sitivity, as well as limb use and weight-bearing deficits on days 7, 
10, 14, 17, 21 and 23. Compared to baseline level, a significant 
decline in the 50% withdrawal threshold, reflecting mechanical 
hypersensitivity, was observed in both females and males from day 
10 to 21 (Figure 2A, Dataset 1: rawdata_vonfrey). Limb use scor-
ing was significantly reduced only on day 23 for the females, but on 
day 17–23 for the males (Figure 2B, Dataset 2: rawdata_limbuse). 
Decline in weight-bearing ratio was significantly reduced on day 17 
and 23 for the females and on day 17–23 for the males (Figure 2C, 
Dataset 3: rawdata_weight-bearing). No significant difference was 
observed between the sexes on any of the test days, however females 
tended to present with a less pronounced limb use and weight- 
bearing deficit in the later phase of disease progression, days 17–23 
(Figure 2B and C).
The relative bone density was significantly reduced compared to 
baseline measures in the males from day 14 and throughout the 
study (Figure 2D, Dataset 4: rawdata_xray). A similar, however 
insignificant, tendency was observed in the females (Figure 2D). 
No difference was found between males and females at any time 
point. Overall, the data suggest a less severe progression in females 
compared to males.
Dataset 1. Rawdata_vonfrey
http://dx.doi.org/10.5256/f1000research.6827.d96687 
Animals were placed in acrylic enclosures on a wire mesh floor 
and allowed to acclimatize for minimum 30 min. Starting at 6 g, 
filaments ranging from 0.4–26 g were applied to the plantar surface 
of the hind paw with a minimum of 3 min intervals between two 
stimulations. A stimulus was recorded as positive if paw withdrawal 
was observed within 3 s of stimulation with a given filament; if no 
response was observed it was recorded as negative. Following 
a positive response, the next stimulation was performed with a 
filament with a decreased bending strength, whereas a negative 
response was followed with stimulation with a filament with 
increased bending strength. The resulting pattern of positive 
and negative responses was calculated into a 50% response 
withdrawal threshold using the formula: 50% g threshold = 
(10Xf+kδ)/(10,000), where Xf = value (log unit) of the final von Frey 
hair used; k = tabular value for the pattern of positive/negative 
responses; and δ = mean difference (in log units) between 
filaments29.
Dataset 2. Rawdata_limbuse
http://dx.doi.org/10.5256/f1000research.6827.d96688 
Following 10 min of acclimation in a transparent plastic cage, each 
animal was observed for 3 min and assigned a limb use score 
from 3 to 0 as follows: 3: Normal use of leg, 2: mild or insignificant 
limping, 1: significant limping, 0: significant limping and part lack 
of use30.
Dataset 3. Rawdata_weight-bearing
http://dx.doi.org/10.5256/f1000research.6827.d96689 
Animals were placed in the incapacitance tester and allowed to 
acclimatize until calm. Measurements were performed over a 
period of 4 s and in triplicates. An average weight-bearing ratio 
was subsequently calculated as the amount of weight placed 
on the cancer-bearing leg divided by the total amount of weight 
placed on both legs and used for data analysis31.
Figure 1.  (A) In vitro quantification of bioluminescence signal. Linear regression demonstrated that the signal increased linearly with the 
number of cells (dotted line), p<0.0001. (B) In vivo quantification. The bioluminescence signal increased during the initial 5min following i.p. 
injection. After 5min the signal reached a stable plateau lasting for approximately 20min. Results from two experiments.
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Dataset 4. Rawdata_xray
http://dx.doi.org/10.5256/f1000research.6827.d96690 
The severity of bone degradation was analysed. The x-ray was 
calibrated to a standard aluminium wedge. The mean grayscale 
value of a standard region of interest within the trabecular bone of the 
proximal tibia was measured and the average of two corresponding 
background regions in the soft tissue proximate to tibia was 
subtracted. The grayscale value was translated into millimeter 
aluminium equivalents (mmAl) according to the standard wedge and 
used as estimate of the relative bone density of the distal femur32.
Females have increased capacity for recovery
All animals had a detectable bioluminescent signal on days 
7 and 10, hence demonstrating successful inoculation of liv-
ing cancer cells (Figure 3, Dataset 5: rawdata_BLI, Dataset 6: 
rawdata_bioluminescence). From day 14 an increasing number 
of animals lost the bioluminescence signal, suggesting recovery 
in a subset of animals. Compared to females with consistent bio-
luminescence signal, a subset of females losing bioluminescence 
signal displayed a significant decrease in the signal from day 17 
(Figure 3). A similar but later occurring tendency was observed in 
the males (Figure 3).
Loss of bioluminescence signal was observed in 40% of the 
females, but only in 20% of the males (Figure 4A and B). A sig-
nificant trend for loss of signal was observed in both females 
and males, p=0.0079 and p=0.0353 respectively. A similar 
pattern in recovery was observed in previous independent 
in-house experiments. In these experiments, lack of osteolysis 
(determined by x-ray analysis) was used as an exclusion cri-
terion. In one study, 5 out of 16 female animals displayed a 
lack of osteolysis (Figure 4C)14. Three additional experiments 
Figure 2. (A) A decrease in 50% withdrawal threshold was observed in both females and males as the disease progressed. (B and C) Males 
demonstrated a significant decrease in limb use and weight-bearing ratio on day 17–23. In contrast, females showed significant decrease 
limb use only on day 23, and decreased weight-bearing on day 17 and 23. (D) A significant decrease in relative bone density was observed 
in the males from day 14. A similar, yet insignificant, tendency was observed in the females. */**/***=males compared to baseline, #/##=females 
compared to baseline.
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Figure 4. (A and B) Cumulative numbers of females and males losing bioluminescence signal over time. (C) Numbers of animals with restored 
states in five independent in-house experiments. The recovery is based on either loss of bioluminescence signal or lack of osteolysis. (D) A 
significant difference is found between the odds ratio of recovering in females and males. *=females compared to males.
Figure 3. Bioluminescence (BLI) signal reflecting progression of tumor growth. The signal increases in both males and females during the 
initial 14 days, and reaches a plateau for the remaining of the study. From day 14 an increasing numbers of animals lost the bioluminescence 
signal. ##/###=females without signal compared to females with signal.
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using male animals demonstrated lack of osteolysis at the end 
of the experiment in 3 out of 21, 1 out of 10 and 1 out of 11 
animals, respectively12 (Supplementary figure S1 and Supple-
mentary figure S2). Pooling the data from the five experiments 
demonstrated a significant difference in the odds ratio between 
females and males, reflecting a significantly greater proportion 
of females clearing active cancer growth compared to males, 
as indicated by loss of bioluminescence signal and/or lack of 
cancer-induced osteolysis, p=0.029, (Figure 4D).
Dataset 5. Rawdata_BLI
http://dx.doi.org/10.5256/f1000research.6827.d96691 
Images were obtained 10min after i.p. injection of 40mg/kg 
Luciferase. Image capture was performed with binning: M(4), F/stop: 1 
and exposure time from 1 s to 60 s according to the power signal. 
For each animal, an average of three images was used for analysis. 
For each image, the threshold was adjusted to 35% of the signal, 
and the readout was measured in total flux, photos/s33.
Dataset 6. Rawdata_bioluminescence
http://dx.doi.org/10.5256/f1000research.6827.d96692 
Representative bio-luminescence images34.
Loss of bioluminescence signal is associated with reversal 
of disease progression
Despite the presence of living cancer cells during the initial 
10 days, neither pain behavior nor relative bone density was 
significantly changed in animals losing bioluminescence sig-
nal (Figure 5A–D). A transient but insignificant decrease in the 
50% withdrawal threshold was observed in animals later losing 
bioluminescent signal (Figure 5A, rawdata_vonfrey). In addi-
tion, a slight decrease in limb use, weight-bearing and relative 
bone density was observed on day 14, however the decrease 
was insignificant and returned to baseline levels on the next 
measured day (Figure 5B–D, rawdata_limbuse, rawdata_
weight-bearing, rawdata_xray). Overall this suggests initial 
Figure  5.  Pain-related behavior  and  relative  bone density  in  animal  losing bioluminescence  signal  during  the  experiment. (A) A 
transient, yet insignificant, decrease was observed in the 50% threshold in females. (B, C) Limb use and weight-bearing deficit was not 
observed in either females or males during the experiment. (D) The relative bone density remained the same throughout the experiment in 
both males and females.
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Figure 6. Correlation between relative bone density and bioluminescence signal. (A) Animals without bioluminescence signal all had high 
relative bone density (blue), whereas animals with high bioluminescence signal demonstrated low relative bone density (black). Examples of 
osteolytic (C) and non-osteolytic bone (D). Examples of high bioluminescence signal (B) and lack of signal (E).
normal disease progression, followed by subsequent recovery 
and hence normal relative bone density and lack of pain behav-
ior. In addition, a strong correlation between bioluminescence 
signal and relative bone density was observed (Figure 6A) 
supporting the division of animals into two groups; animals 
with a clear bioluminescence signal and osteolysis, indicating 
active cancer growth (Figure 6A, B and C) and animals with no 
bioluminescence signal and no osteolysis, indicating recovery 
(Figure 6A, E and D).
Sex-difference screws progression of pain behavior
Exclusion of animals successfully recovering aligned the onset and 
severity of pain behavior in both sexes (Figure 7A–C). In addition, 
a similar effect was seen on the relative bone density, reflecting 
similar bone degradation in both females and males with active 
growing cancer (Figure 5D). No significant difference was observed 
between females and males at any time point.
Discussion
To increase the translational potential of preclinical research, it is 
essential to continually focus on refining and optimizing the animal 
models used. Increased focus has been given to sex as a variable, 
initially driven by the contradictive issue that preclinical research has 
been biased towards use of male animals despite the fact the chronic 
pain is highly overrepresented in women8. Although females are in 
most cases likely the most intuitive sex for models of metastatic breast 
cancer, such as the MRMT-1 model of cancer-induced bone pain, our 
data suggest that care should be taken when interpreting the data. 
Our data demonstrates that the females have an increased capacity 
for recovering from the disease state, reflected by loss of biolumines-
cence signal accompanied by normal limb use and weight-bearing 
ratio as well as normal relative bone density throughout the study.
The increased odds ratio for recovery in the females introduces a 
potential bias in interpretation of the data. Importantly, although 
there is no significant difference between females and male, the 
increased recovery in the females pulls the mean of the females’ 
readouts towards baseline to a much greater degree than the males, 
thereby increasing the risk of underestimating the severity of the 
disease in the females. In order to get a reliable model truly reflect-
ing the human disease, it is critical to exclude the animals capa-
ble of recovery, as these animals are not reflecting the pain state 
observed in patients. This means that it is highly important to 
include a parameter for discrimination between an “active disease 
state” and a “recovered from disease state”. Inclusion of animals 
with recovered states clearly mask the severity of the disease in the 
females, as limb use is only significantly decreased on the last day 
and the relative bone density is not significantly affected at any time 
point (Figure 2A and D). However, excluding females with recov-
ered disease state reveals that females are in fact severely affected 
at an earlier time point, demonstrated by an significant decrease in 
limb use already on day 17 and in addition significant decreased 
relative bone density from day 21 (Figure 7B and D).
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In addition, our data demonstrates that bioluminescence signal is 
a reliable measure for the active disease state. All animals with 
continuous bioluminescence signal subsequently developed pain-
related behavior and decreased relative bone density. In contrast, 
animals losing bioluminescence signal during the experiment did 
not develop pain-related behavior and demonstrated normal relative 
bone density. This is in agreement with other studies demonstrat-
ing that bioluminescence signal is predictable measure for quanti-
fication of cancer cells in vivo15,16. To further validate the recovery 
state, histology could be made to confirm that loss of biolumines-
cence signal is actually caused by clearance of the cancer cells 
and not just loss of signal from the cancer cells. However, since 
the first model of cancer-induced bone pain was developed, bone 
degradation has been demonstrated to associate with tumor burden 
numerous times17–21. In this study, the loss of bioluminescence 
signal is accompanied by lack of bone lesions and in addition lack 
of pain behaviors making it highly unlikely that there is still active 
cancer growth in the animals.
Importantly, this study emphasizes the need to consider sex- 
dependent variation beyond simple disease readouts. The data dem-
onstrate that there are not significant difference between females and 
males with respect to pain behavior and bone degradation. However, 
there are sex-differences in the model which needs to be carefully 
considered when modeling cancer-induced bone pain in females, as 
the increased recovery rate in the females can potentially mask the 
progression. The specific mechanisms underlying the sex-dependent 
difference in recovery are currently not known, and requires an 
Figure  7.  Pain-related  behavior  and  relative  bone  density  in  animals  with  a  consistent  bioluminescence  signal  throughout  the 
experiment. (A, B and C) Both females and males demonstrate significant decreases in 50% withdrawal threshold, limb use score and 
weight-bearing ration. (D) Both sexes show a similar extent of bone degradation. **/***/****=males compared to baseline, #/##/####=females 
compared to baseline.
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extensive investigation of hormonal and cellular responses. One 
potential cause could be sex-dependent differences in the immune 
responses. It is now generally accepted that inherent properties and 
influence of sex hormones induce more potent immune and inflam-
matory reactions in females compared to males22,23. An intuitive 
cause could therefore be, that the females’ increased recovery rate is 
linked to an increased immune response to inoculation with the can-
cer cells possible modulated by sex hormones. It should be noted 
that the capacity for recovering was seen regardless of whether 
the cancer cells expressed luciferase or not, and is thus not due 
to an immune reaction to the luciferase enzyme. However, as the 
MRMT-1 are estrogen receptor-postive20, the relationship might not 
be so simple. Estrogen generally cause increase growth in estrogen 
receptor-positive cells24, suggesting that the female immune system 
would have to fight a more rapidly growing tumor, which would 
suggest a lower recovery rate. A full understand of the involvement 
of sex hormones on the progression of MRMT-1 requires exten-
sive studies; however our data suggest a minor role in the overall 
progression of cancer-induced bone pain in this model. This is 
also supported by the similar progression in males and female rats 
despite the estrogen receptor-positives status of the cells.
In addition, recent work from Sorge et al. demonstrate that differ-
ent cells mediates pain hypersensitivity in female and male mice25. 
They found that although the males and females developed the 
same degree of mechanical allodynia following nerve injury, there 
was a fundamental difference in the cellular involvement. Whereas 
microglia activity was required for mechanical pain hypersensitivity 
in males, this was not the case in females, where the hypersensi-
tivity was driven by adaptive immune cells, likely T lymphocytes. 
Our data suggest that a similar phenomenon could be involved in 
progression of MRMT-1 induced cancer pain. In agreement with 
Sorge et al., we find a similar pain response in females and males, 
however since there is a significant difference in the recovery rate 
between the sexes, it might indicate the different systems are medi-
ating the pain state in female and male rats.
Another factor potentially affecting the sex-dependent effect might 
be the local microenvironment in the bone. The microenvironment 
around the tumor might be different due to nonspecific sex-differ-
ences, hence potentially affecting the growth of the tumor cells 
following inoculation26–28. Interestingly, the observed difference is 
likely species or cell line dependent. We have previously reported 
that in a similar model of cancer-induced bone pain, based on 4T1-
luc2 mammary cancer cell inoculation in femur of BALB/cJ mice, 
females have a significantly greater initial bioluminescence signal 
compared to males. The females had, in addition, an earlier onset 
of pain behavior, but a similar bone degradation rate5. This sug-
gests that in the mouse model, intrinsic sex-dependent variation 
favors more aggressive progression in females compared to males, 
whereas the rat model displays better odds ratio for recovery in the 
females.
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Supplementary  figure S2. Representatives of animals demonstrating bioluminescence signal (A–C,  E,F) and lack of bioluminescence 
signal (D).
Supplementary figure S1. Representative images of animals demonstrating osteolysis (A–F) and lack of osteolysis (G,H).
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I read the paper with interest and, although I do not always agree with the authors’ interpretation of the
data, I found the study thought-provoking and analysis thorough and complex.
In my view, the main result of the study is that even though initial analysis demonstrates some
difference between male and female animals inoculated with breast carcinoma cells, after the
animals that spontaneously recovered from the disease were excluded, this difference between
sexes was no longer evident. To me, this says that the process of cancer establishment in the
bone is very similar in animals of different sex. This is a very interesting conclusion, however, to
strengthen it I suggest to run the statistical analysis to directly compare male and female animals
for figure 2 and 7, since it is possible that even though male and female animals behave
(somewhat) differently compared to their respective baselines, there could be no significant
difference between the sexes on Fig 2, which would dilute the impact of the conclusion. If that is
the case, then the man focus of the study would become the difference in the percentage of
animals spontaneously recovered from cancer inoculation.
 
I think the critical information missing from the description is the status of MRMT-1 cells with regard
to estrogen and progesterone receptors. I have never worked with this cell line and I couldn’t find
from the quick search if it is ER, PR positive or negative. I believe this information is critical both for
interpretation of the difference in the cancer clearance rate between male and female animals, and
the lack of difference in lesion progression between male and female animals.
 
I agree with Dr. Jiménez-Andrade that the sensitivity of the analysis of bone lesions based on
grayness of X-rays is limited and that bone histomorphometry will significantly strengthen the
conclusions.
 
I was confused with the last paragraph in Discussion on potential contributors to the difference in
pain measures in male and female animals, when the conclusion of fig 7 is that there is no such
difference.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard, however I have significant reservations, as outlined
above.
 No competing interests were disclosed.Competing Interests:
Author Response 09 Nov 2015
, University of Copenhagen, DenmarkSarah Falk
We thank Dr. Komarova for the helpful comments, and acknowledge that the study is somewhat
untraditional in the sense that the main focus is on the increased variation observed in the females,
which can potentially bias the model, rather than on a direct comparison on differences in readouts
between males and females. Based on the reviewers useful criticism the following has been
address and clarified in the discussion:
The reviewer is completely right; although the lack of difference between progression in
female and male rats are on its own highly important for working with the model, the main
result is not a direct comparison between sexes, but rather the differences in percentages of
animals spontaneously recovering, and hence the indirect effect on variation in females and
males. A statistical analysis comparing females to males was performed, and is mentioned
in result section describing figure 2. The same analysis was performed for the data in figure
7, but was mistakenly not directly mentioned in the result section, this has been added. The
main point is, as pointed out by the reviewer, the difference in ratio of spontaneous recovery
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main point is, as pointed out by the reviewer, the difference in ratio of spontaneous recovery
between the sexes, which needs to be considered when working with the model in females,
as the increased recovery rate can potentially mask the progression in females.  Elaboration
on this has been added to the discussion.
 
The MRMT1 cells line has been reported to be estrogen positive . This seems
counterintuitive as a negative status for the MRMT1 cells could possible explain the lack of
difference in progression between the sexes, but here other factors seems more important.
In addition, as estrogen is known to increase the growth of ER-positive tumors, the
ER-positive status does not explain the increased recovery in females. If anything the
ER-positive status of MRMT-1 cells should in theory have an opposite effect, hence
decrease the likelihood of recovery in females. A section on this has been added to the
discussion.
 
It is true that X-ray analysis for quantification of bone lesions provides much less detailed
information as compared to histomorphometry. However X-ray analysis for quantification of
bone lesions is widely used in the literature, and has been extensively demonstrated to
associate with degree of tumor burden quantified by histology since the first model was
described by Schwei in 1999 . Also, in this study the conclusion that the rats recover from
the cancer is not solely based on the x-ray data but also on bioluminescene and
pain-related behavior. A further discussion of this has been added to the discussion.
 
The paragraph regarding the recent study by Sorge et al is included to make attention to the
fact that although the outcome of a condition may be the same, the underlying mechanisms
can be different. Sorge et al demonstrate that although male and females displays the same
degree of mechanical allodynia following nerve injury, the underlying mechanisms are
different. We suggest that a similar phenomenon could be responsible for the data reported
in this study.  Despite a similar outcome in terms of pain behavior the underlying
mechanisms driving the pain might be mediated by different systems, which are likely linked
to the observed sex-differences in recovery rates. This has now been clarified in the
discussion.     
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, McGill University, CanadaKomarova Svetlana
Thank you for your response. I believe that new discussion provides a significant and novel focus
for the study. 
 No competing interests were disclosed.Competing Interests:
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 Juan M Jiménez-Andrade
Unidad Académica Multidisciplinaria Reynosa-Aztlán, Universidad Autónoma de Tamaulipas (UAT),
Reynosa, Mexico
This is very interesting and well presented study; however the data does not support the title and
conclusions at all of the present study. For this reviewer it is unclear what is the functional implication of
females having an increased capacity for recovering from cancer state, given that there are
non-significant differences in terms of pain behaviors and bone degradation between females and male
rats. I think the authors are overstating the results and the results are not properly interpreted.
Additionally, the authors have not considered that the loss of bioluminescence signal over time may due
to gender-related differences in terms of bioavailability and excretion of D-Luciferin. In fact, the authors
are strongly recommended to present the  quantification of bioluiminescence signal after i.p. in vivo
injection (as presented in figure 1B) in both females and males.
Finally, a histopathological analysis of the bone is strongly needed in order to suggest that females rats
are recovering faster than male rats. 
EDIT 21/08/2015: This review was mistakenly published with a ‘Not Approved’ status, this has
now been amended to an ‘Approved with Reservations’. The text has not been changed in any
way.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
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I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard, however I have significant reservations, as outlined
above.
 No competing interests were disclosed.Competing Interests:
Author Response 10 Sep 2015
, University of Copenhagen, DenmarkSarah Falk
Dear Professor Jiménez-Andrade
 
Thank you for your very constructive review. We have taken your comments into carefully
consideration, and made the following changes:
 
We have changed the title to “Effect of sex in the MRMT-1 model of cancer-induced bone pain”, as
we realize that the original title could be misleading.
 
Regarding the functional implication of the study, we have extended the discussion to clarify that
the main result of the study is the increased capacity for recovery from the tumor-induced disease
in the female rats compared to the male rats. This can potentially affect the interpretation of data
produced with the model.
The last line in the abstract is in addition changed to “interpretation of data”, to emphasize that the
increased capacity for recovery do not affect the overall progression in cancer-bearing animals, but
that the recovery in some animals can mask the actual effect of the cancer, as the data from the
recovered animals will shift the mean towards baseline. 
 
Sex-related differences in terms of bioavailability and excretion of D-Luciferin should not affect the
result in the study. The bioluminescence emission is based on acute injection of D-Luciferin at a
level that saturates the system. Bioluminescence signal is measure 10min past injection on each
measure day, meaning that if there were sex-differences in bioavailability and excretion is should
be seen on all measuring day, and not only in a subset of animals from day 17 and beyond. Also as
can be seen in supplement figure S2 the loss of signal is seen as an all-or-non response; either
there is a signal or no signal at all. If the loss of bioluminescence signal were caused by changes in
bioavailability and excretion in a subset of animals a more gradient decrease in signal would be
expected and not a complete loss of signal as seen in these animals.
 
Additional histopathological analysis could be performed, however since loss of bioluminescence
signal is accompanied by both lack of pain behavior and osteolysis it is unlikely that the animals
should have living cancer cells in tibia. To emphasis this point, we have added a section in the
discussion. 
 No competing interests were disclosed.Competing Interests:
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